EEI SUNBURNS ACCORDING TO GENDER  by Guitera, P et al.
653Abstracts
costs for cohort B were substantially higher than for cohort A
($8312 + $11,218, versus ($11,760 + $18,155, p = 0.03). CON-
CLUSIONS: The persistent use of OXC provided a less costly
alternative for managed care organizations among patients
switched to OXC after initial monotherapy failure. This study
ﬁnding encourages the clinical practitioner to promote patients’
persistency on the OXC monotherapy when medically appro-
priate.
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OBJECTIVES: According to current guidelines, there is no hier-
archy between antiepileptic drugs (AED), and the choice should
take into account efﬁcacy, tolerability, pharmacokinetic proper-
ties, impact on quality of life, patient preference and cost. Older
AEDs such as carbamazepine and valproate are often prescribed,
with cost constraints cited as reason for the treatment choice.
Given the relative scarcity of long term comparative trials, eco-
nomic modelling is appropriate to assess whether lower drug
costs justify the use of older AEDs. METHODS: A Markov
model was developed to capture long-term outcomes (1–15
years) of treatment strategies (ﬁrst- and second-line monothera-
pies). Expected treatment costs (routine medical costs, adverse
event costs, and drug costs) were calculated by disease severity
for 2004 from the perspective of a third party payer. Results of
a discrete choice experiment exploring whether people with
epilepsy were willing to trade months of life against improve-
ments in seizure control and side effects were used to calculate
expected utilities. A range of relevant sensitivity analyses were
undertaken. RESULTS: At one year, treatment with only older
AEDs was least costly, but also resulted in the lowest QALY
gains. Both the use of topiramate instead of an older AED as
second-line, or instead of an older AED as ﬁrst-line were asso-
ciated with incremental cost-effectiveness ratios (ICER) between
20,000€ and 30,000€/QALY gained. At longer time horizons
both the ICER of offering topiramate second-line, and the ICER
of offering topiramate ﬁrst-line gradually improved. CONCLU-
SIONS: Topiramate either as ﬁrst- or second-line monotherapy
delivers extra health beneﬁts for a slight and acceptable increase
in costs, showing that topiramate treatment is cost-effective. The
decreasing ICERs over time show the importance of longer treat-
ment retention. Choice of AED should therefore be based on
patient-speciﬁc criteria only.
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OBJECTIVES: To prospectively evaluate the health economic
burden of patients with Parkinson’s disease (PD) in Germany
over a 12-months observation period. METHODS: Direct and
indirect costs were evaluated in 145 patients with PD (mean age:
67.3 ± 9.6 years) in Germany. Clinical evaluations were per-
formed at baseline, 3, 6 and 12 months. Relevant economic data
were documented in a special patient diary over the 12-month
period. Costs (2002€) were derived from various German
medical economic resources. Costs were calculated from the per-
spective of health insurance (Gesetzliche Krankenkassse, GKV),
transfer payment providers and the individual patient. Costs are
presented as means ± standard deviation (SD). RESULTS: We
estimated per patient direct, indirect, and total costs for the
twelve-month period. The costs from the perspective of the
health insurance GKV consist of direct medical costs 3770 ±
7020€; including rehabilitation (1080 ± 3320€), hospitalization
(2200 ± 5590€), outpatient treatment (80 ± 50€), non-medical
treatment (390 ± 580€) and ambulatory diagnostic procedures
(20 ± 40€). In addition, drug costs for anti-parkinsonian treat-
ment were 3350 ± 2720€. Non-medical direct costs calculated
from the GKV perspective were estimated to be 1040 ± 3350€,
which included transportation (30 ± 50€), special equipment
(880 ± 3100€), social services (30 ± 310€), and sickness beneﬁt
(110 ± 1330€). The total medical (including drug costs) and 
non-medical direct costs for the GKV were 8160 ± 8770€
and depends on disease severity and the occurrence of motor 
complications. For the nursing insurance payments of 2990 ±
6590€ were calculated, for the retirement insurance 1410 ±
3210€, and patient and caregiver costs of 3150 ± 5320€. Total
indirect costs amounted to 6590 ± 13,150€. On average, a total
of 22,400 ± 25,410€ per patient were attributable to PD. CON-
CLUSION: The result of the study clariﬁes the high ﬁnancial
burden of PD on society and patients. This underscores the need
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To feel personally concerned with a risk, one needs to experience
it. OBJECTIVES: The ICARE programme’s objective is to asses
patients’ knowledge of the consequences of sun exposure.
METHODS: Every patient coming to an outpatient pharmacy in
order to obtain advice or treatment following a sunburn was
remitted a questionnaire assessing their knowledge of the conse-
quences of sun exposure. RESULTS: Men and women act dif-
ferently towards sun exposure. If 41% expose themselves more
than 2 hours per day (W 40%, M 43%) and if more than 50%
expose themselves between 11h00 and 16h00, then more than
70% do it after 16h00. The only difference concerns sun expo-
sure before 11h00, for which 35% of women and only 19% of
men are concerned (p = 0.03). Concerning sun protection with
protective skin lotions, 59% of women report applying them reg-
ularly vs. 33% of men (p = 0.003). The back and arms are the
most often expressed localisation sunburns for women (50% and
43%) vs. the back and face for men (52% and 38%). Eight
percent (8%) admitted that their sunburn messed their vacation
up, 38% reported sleep disturbance and 26% couldn’t do what
they wanted because of their sunburn. Assessment of QoL using
the DLQI showed evidence of quality of life impairment stronger
for women than for men, mean scores being respectively 4.89
and 2.72 (p < 0.05). CONCLUSIONS: The results of our study
are similar to the one of McCarthy et al where men exhibited a
signiﬁcantly higher frequency of sunburn, employed fewer sun-
protective measures, and demonstrated less knowledge concern-
ing sun safety information and skin cancer than women. The
direct consequence of this is a profound impairment of quality
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of life for men (DLQI mean score of 4.89) compared to women.
This score reﬂects quality of life impairment similar to patients
suffering from acne or solar keratosis.
EE2
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OBJECTIVES: To assess the consequences of dermatological dis-
eases on the quality of life of the patients and to perform an eval-
uation of depressive symptomatology among them. METHODS:
Every Belgian Dermatologist received a sample of 30 question-
naires including the DLQI, the SF-12 and the CES-D. During the
“National Week of Dermatology”, each participating dermatol-
ogist distributed the questionnaire to their ﬁrst 30 patients
coming to their consulting room and they made a register of all
the dermatological diseases of their patients. The CES-D scale
allows to perform epidemiological studies of depressive sympto-
matology in the general population. A score >17 indicates a pos-
sible depressive symptomatology, a score >23 indicates a
probable depressive symptomatology. RESULTS: In total, 105
out of the 650 Belgian dermatologists completed the register. A
total of 896 questionnaires were by 513 Flemish responders
(57%) and 383 Walloon responders (43%). The male/female
ratio was 37%/63% and the mean age was 46.76 years. The
disease allocation was: Psoriasis 15%, Atopic Dermatitis &
Contact Eczema 11%, Acne 11%, Warts 9%, Dry skin 8%,
Others 46%. Possible depressive symptomatology was observed
in 36% of the population (Flemish patients: 32%; Walloons
patients: 44%). Concerning probable depressive symptomatol-
ogy, 20% of our population (Flemish patients: 17%; Walloons
atients: 26%, p < 0.01). CONCLUSIONS: Although females
generally reported greater risk of high depressive symptoms, this
is still a concern for males. In the Rield study assessing depres-
sive symptoms in older men and women (age 65 to 75), 23.1%
of women and 12.8% of men reported high depressive symp-
toms (CES-D score > or = 16). When we compare those results
with the ones obtained in our current study, it conﬁrms that der-
matological diseases result in psychological changes that seri-
ously affect patients’ lives.
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OBJECTIVES: There is a wide range of treatments for moder-
ate-to-severe psoriasis, including oral systemics, biologics, and
phototherapies; we evaluated their cost-effectiveness (in US
dollars). METHODS: We conducted a systematic review of pub-
lished, clinical studies from 1978 to 2004 describing outcomes
for moderate-to-severe psoriasis in terms of the Psoriasis Area
and Severity Index (PASI). We determined the weighted mean
PASI improvement across studies for acitretin, alefacept,
cyclosporine, efalizumab, etanercept, inﬂiximab, methotrexate,
narrowband ultraviolet B (NBUVB), broadband ultraviolet B
(BBUVB), psoralen with ultraviolet A (PUVA), BBUVB combined
with acitretin, and PUVA combined with acitretin. The model
perspective is of the US health systems payer, and includes 1-year
medication (US Average Wholesale Price) and related treatment
(Medicare reimbursement) costs. Cost-effectiveness (deﬁned as
the cost per 1% PASI improvement) was calculated as: Total
Treatment Costs [medications or phototherapy + administration
of treatment (e.g., IV infusion) + monitoring (e.g., diagnostic
procedures) + risk-adjusted costs of adverse events] divided by
mean PASI improvement. RESULTS: We found wide variation
in annual drug costs, ranging from $1388 (methotrexate) to
$24,894 (inﬂiximab). Annual costs of treatment administration
ranged from $0 (oral systemics) to $1438 (inﬂiximab). Annual
costs of monitoring ranged from $0 (etanercept) to $2,306 (ale-
facept). Risk-adjusted costs of adverse events ranged from $0 to
$98. PASI improvement varied from 37% (alefacept 15mg IV)
to 85% (PUVA with acitretin). The annual cost per 1% PASI
improvement was: $37 for methotrexate, $46 PUVA, $91
cyclosporine, $120 NBUVB, $166 PUVA with acitretin, $167
BBUVB with acitretin, $197 acitretin, $265 BBUVB, $325 inﬂix-
imab, $357 efalizumab, $390 etanercept, and $472 alefacept IM.
CONCLUSIONS: Costs of medication and efﬁcacy rates are the
primary drivers of the cost-effectiveness of treatments for mod-
erate-to-severe psoriasis. New biologic treatments do not appear
as cost-effective as oral systemic agents, phototherapy, or com-
bined phototherapy with oral systemics.
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OBJECTIVES: To compare the expected U.S. payer costs asso-
ciated with screening and early treatment of glaucoma patients
vs. non-screening of this asymptomatic progressive disease.
METHODS: A 14-year economic model was developed to eval-
uate costs associated with biennial screening and early treatment
and compare it to not-screening, resulting in patients presenting
at slightly more advanced mild stages of this progressive disease.
Total costs included screening costs, drug costs, ofﬁce visits, and
surgical treatments associated with glaucoma. Treatment costs
and disease progression rates were taken from recently published
literature. Non-screened patients were assigned zero costs for
seven years followed by treatment costs for mild disease for seven
years. Screened patients were assigned every-other-year screen-
ing cost for 14 years, with a proportion of screened patients at
risk assigned early/mild glaucoma treatment costs. Patient epi-
demiology rates were based on non-Medicare patients aged
40–64 years old. Multi-factor sensitivity analyses were con-
ducted. RESULTS: Total expected costs to “screen and treat”
over 14 years are estimated to be $8,910 per patient or $636 per
patient per year compared to “not-screen” for 7 years followed
by 7 years of treatment costs of $10,458 or $1,494 per patient
per treated year. In sensitivity analyses, the difference in total
expected plan costs varies around cost-neutral. CONCLU-
SIONS: Total expected payer costs for screening for glaucoma
will be cost neutral over the early years of the disease and will
be cost saving during the more expensive progressive years. Cost
considerations must be balanced with patient concerns of
advancing to blindness and patient/plan beneﬁt with this new
HEDIS measure.
